Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT03694522
Title	A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer (FIGHT)
Acronym	FIGHT
Recruitment	Completed
Gender	both
Phase	Phase II
Variant Requirements	Yes
Sponsors	Five Prime Therapeutics, Inc.
Indications	gastroesophageal junction adenocarcinoma gastric adenocarcinoma
Therapies	Bemarituzumab + Fluorouracil + Leucovorin + Oxaliplatin Fluorouracil + Leucovorin + Oxaliplatin
Age Groups:	senior \| adult
Covered Countries	USA \| TUR \| ROU \| POL \| ITA \| HUN \| GBR \| FRA \| ESP \| DEU \| BEL \| AUS